No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Cuts Target Price to $12
Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views
Y-mAbs Therapeutics Price Target Cut to $12.00/Share From $22.00 by HC Wainwright & Co.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Top Premarket Gainers
Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS Estimates